Ferring Pharmaceuticals has launched testosterone replacement therapy Testavan in the UK.
News
Keapstone satisfies conditions for further £1m investment
Virtual biotech Keapstone Therapeutics is in line for a further £1 million investment from Parkinson’s UK to move forward its innovative disease-modifying therapeutic approach to motor neuron disease (MND) and Parkinson’s.
Novartis to file Lucentis for rare sight condition in premature babies
Novartis has revealed its intent to file anti-VEGF therapy Lucentis for retinopathy of prematurity (ROP), a rare disease in premature infants that often leads to blindness.
EU approves new option for metastatic melanoma
The European Commission (EC) has granted marketing authorisation for Pierre Fabre’s Braftovi and Mektovi combination therapy for the treatment of adults with unresectable or metastatic melanoma with a BRAFV600 mutation.
CHMP puts 13 therapies forward for EU approval
Marking a bumper month for Committee for Medicinal Products for Human Use (CHMP) decisions, 13 medicines have been put forward for approval in the region, including three orphan medicines.
High Court rejects Novartis, Bayer’s bid to outlaw off-label Avastin
Bayer and Novartis have lost a landmark case in the UK seeking to prevent the off-label use of Roche’s Avastin to treat wet AMD, a leading cause of sight loss in the elderly.
Medical & Scientific Excellence Awards – Have you entered yet?
New from PharmaTimes Media is the Medical & Scientific Excellence Awards.
Highlighting this important area of work within the pharmaceutical industry, the awards are designed to recognise the outstanding achievements of medical and scientific professionals.
2018 PM Society Digital Awards winners announced
Bedrock, DDB Remedy and Insypher lead the agency field, Gilead tops the pharma chart
ABPI enters five-year partnership with AHSN
The Association of the British Pharmaceutical Industry (ABPI) is linking arms with the Academic Health Science Network in a five-year partnership that strives to accelerate uptake of transformative biomedical innovations by the NHS
Celgene walks away from Oncomed’s navicixizumab
Celgene has decided not to exercise its option to license OncoMed’s bispecific antibody navicixizumab.
Daiichi to test cancer drug combo
Daiichi Sankyo has entered into a clinical trial collaboration agreement with a subsidiary of MSD to evaluate a potential new combination therapy for breast or lung cancers.
CR UK forms £30m partnership with EU cancer charities
Cancer Research UK is partnering with European cancer research charities AIRC (Associazione Italiana per la Ricerca sul Cancro) and FC AECC (Asociación Española Contra el Cáncer) to invest around £30 million in six international collaborations aiming to accelerate progress in translational research.
Setback for Pharming’s bid to expand use of Ruconest
US regulators have turned down Pharming’s application to expand the approved uses of Ruconest to include prophylaxis in patients with hereditary angioedema (HAE).
EU green light for new Humira biosimilar
The European Commission has approved Mylan and Fujifilm Kyowa Kirin Biologics’ Humira biosimiar Hulio.
Astellas’ kidney disease drug shows promise in PhIII
A Phase III study assessing Astellas’ roxadustat in patients with chronic kidney disease (CKD) and anaemia who are not receiving dialysis has met its key endpoints.
